Management of atherogenic dyslipidemia according to current treatment guidelines: DESPEGA study in real clinical practice

  • Jesús Núñez-Cortés
  • Patricia Rodríguez-Fortúnez
  • Malena Melogno-KlinkasEmail author
  • Marta Rodríguez de Miguel
  • Susana Aceituno
  • Maria Luisa Orera-Peña
Original Research Article



Studies in patients with dyslipidemia have revealed that, despite guideline recommendations, treatment remains unchanged even when therapeutic goals are not achieved.


Our objective was to determine the degree to which primary care (PC) and specialty care (SC) physicians adhere to clinical guidelines for the management of atherogenic dyslipidemia (AD).


This was an observational, descriptive, cross-sectional study. Physicians working in the Spanish Health System completed an electronic questionnaire comprising 24 items organized into three blocks: clinical guidelines, adherence to clinical guidelines, and other issues in the management of AD. The questions were formulated with closed polytomous or categorized responses. Adherence to guidelines, in terms of treatment, was assessed according to physicians’ responses to six patient profiles. Absolute and relative frequencies (qualitative variables), central tendency and dispersion (quantitative variables) were calculated.


In total, 980 physicians (88.5% PC) participated in the study; 77.3% used guidelines in their routine clinical practice, with the most used being the Spanish SEMERGEN (73.8%) and the European Society of Cardiology/European Atherosclerosis Society guidelines (41.2%). A total of 83% adhered to guideline recommendations in more than four of the six profiles proposed, 26.2% adhered to the SEMERGEN definition of AD, 66.6% combined all lipoprotein ratios to diagnose AD, and > 60% used non-high-density lipoprotein cholesterol (HDL-C) to diagnose patients with AD at high cardiovascular risk. In total, 99.0% prescribed a fibrate to reduce triglyceride levels, 47.4% to increase HDL-C levels and 40.2% to reduce small, dense low-density lipoprotein cholesterol particles.


Since adherence to clinical guidelines improves both the quality of care and health outcomes, greater adherence to and satisfaction with clinical guidelines for the management of AD may contribute to improvements in and optimization of the management of patients with AD in the Spanish health system.



The authors acknowledge the physicians who participated in this study. They also acknowledge Mariona Lería (Medical Department Head/Product Safety & Risk Management) and Outcomes’10 for support with the study coordination.

Compliance with ethical standards

Data confidentiality

Data confidentiality of all participants was respected at all times. Information about the identity of the participants was considered confidential for all intents and purposes and was stored and handled in accordance with Organic Law 15/1999 of 13 December 1999 on the Protection of Personal Data.

Informed consent

All study participants received adequate information and agreed to participate before inclusion.


This study was sponsored by BGP Product Operations S.L (Mylan).

Conflict of interest

JMNC has no conflicts of interest that are directly relevant to the content of this article. PRF, MMK, MRM and MLOP work at BGP Product Operations S.L (Mylan). SA works for an independent research organization (Outcomes’10, S.L.), which has received fees for contributions to the development and coordination of the project and to the writing of this manuscript.

Supplementary material

40267_2019_605_MOESM1_ESM.docx (30 kb)
Supplementary material 1 (DOCX 30 kb)


  1. 1.
    Millan Nuñez-Cortés J, Pedro-Botet Montoya J, Pintó Sala X. Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014. Clin Investig Arterioscler. 2014;26:287–92.Google Scholar
  2. 2.
    Rodríguez Á, Núñez-Cortés JM, Blasco Valle MPEF. Guía clínica para la detección, diagnóstico y tratamiento de la dislipemia aterogénica en atención primaria. 2013.énica.pdf. Accessed June 2018.
  3. 3.
    Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301–10.CrossRefGoogle Scholar
  4. 4.
    Buring JE, Mora S, Sacks FM, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2015;298(3):309–16.Google Scholar
  5. 5.
    Lau DCW, Yan H, Dhillon B. Metabolic syndrome: a marker of patients at high cardiovascular risk. Can J Cardiol. 2006;22(Suppl B):85B–90B.CrossRefGoogle Scholar
  6. 6.
    Millán J, Hernández-Mijares A, Ascaso JF, et al. La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico. Clin Investig Arterioscler. 2016;28:265–70.Google Scholar
  7. 7.
    Sánchez-Chaparro M, González-Santos P, Valdivieso-Felices P, et al. Prevalencia de dislipidemiaaterogénica en población laboral Española. Grupo de Estudio “ICARIA”. 18a Reunión Nacional de la Sociedad Española de Hipertensión, Liga Española para la Lucha contra la Hipertensión Arterial. Valencia, 6 al 8 de Marzo, 2013.Google Scholar
  8. 8.
    Ascaso JF, Millán J, Hernández-Mijares A, et al. Documento de consenso sobre el manejo de la dislipemia aterogénica de la Sociedad Española de Arteriosclerosis. Clin Investig Arterioscler. 2017;29:86–91.Google Scholar
  9. 9.
    Pedro-Botet J, Millán J, Brea Á, et al. Decálogo de recomendaciones clínicas en dislipidemia aterogénica. Clin Investig Arterioscler. 2014;26:38–40.Google Scholar
  10. 10.
    Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818.CrossRefGoogle Scholar
  11. 11.
    Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.CrossRefGoogle Scholar
  12. 12.
    Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314–45.CrossRefGoogle Scholar
  13. 13.
    Moutzouri E, Kei A, Elisaf MS, et al. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag. 2010;6:525–39.Google Scholar
  14. 14.
    Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220–6.CrossRefGoogle Scholar
  15. 15.
    Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–28.CrossRefGoogle Scholar
  16. 16.
    Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010;17(5):530–40.CrossRefGoogle Scholar
  17. 17.
    Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459–67.CrossRefGoogle Scholar
  18. 18.
    Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction : data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38–44.CrossRefGoogle Scholar
  19. 19.
    Goldberg KC, Melnyk SD, Simel DL. Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. Am J Manag Care. 2007;13:530–4.Google Scholar
  20. 20.
    Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000;321:1322–5.CrossRefGoogle Scholar
  21. 21.
    Martínez-Hernández A, Aguilar-Leñero M, Mengíbar MR, et al. Prevención secundaria de cardiopatía isquémica a nivel lipídico en atención primaria Aragón. Estudio PRECIAR. Rev Esp Salud Pública. 2001;75:143–50.CrossRefGoogle Scholar
  22. 22.
    Banegas JR, Vegazo O, Serrano P, et al. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis. 2017;188(2):420–4.CrossRefGoogle Scholar
  23. 23.
    Lázaro P, Murga N, Aguilar D, et al. Inercia terapéutica en el manejo extrahospitalario de la dislipemia en pacientes con cardiopatía isquémica. Estudio Inercia. Rev Española Cardiol. 2010;63:1428–37.CrossRefGoogle Scholar
  24. 24.
    Ministerio de Sanidad, Política Social e Igualdad. Informe sobre oferta y necesidad de especialistas médicos en España. 2010–2025. 2011. Accessed Nov 2016.Google Scholar
  25. 25.
    Alfonso F, Bermejo J, Segovia J. Guías Europeas de Práctica Clínica en Revista Española de Cardiología. ¿Hacia una completa «globalización» de la asistencia cardiovascular? Rev Española Cardiol. 2004;57:1000–2.CrossRefGoogle Scholar
  26. 26.
    Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527–30.CrossRefGoogle Scholar
  27. 27.
    Constantino-Casas P, Viniegra-Osorio A, Medécigo-Micete C, et al. El potencial de las guías de práctica clínica para mejorar la calidad de la atención. Rev Med Inst Mex Seguro Soc. 2009;47:103–8.Google Scholar
  28. 28.
    Vashitz G, Meyer J, Parmet Y, et al. Physician adherence to the dyslipidemia guidelines is as challenging an issue as patient adherence. Fam Pract. 2011;28:524–31.CrossRefGoogle Scholar
  29. 29.
    McKinlay JB, Link CL, Freund KM, et al. Sources of variation in physician adherence with clinical guidelines: results from a factorial experiment. J Gen Intern Med. 2007;22:289–96.CrossRefGoogle Scholar
  30. 30.
    Kenefick H, Lee J, Fleishman V. Improving physician adherence to clinical practice guidelines: barriers and strategies for change. Cambridge: New England Healthcare Institute (NEHI); 2008.Google Scholar
  31. 31.
    Soutelo J, Graffigna M, Honfi M, et al. Índice triglicéridos/HDL-colesterol: en una población de adolescentes sin factores de riesgo cardiovascular. Arch Latinoam Nutr. 2012;62:167–71.Google Scholar
  32. 32.
    Pallarés-Carratalá V, Esteban-Giner MJ, Giner-Galvañ V. Overview of guidelines for the management of dyslipidemia: EU perspectives. Vasc Health Risk Manag. 2016;12:357–69.CrossRefGoogle Scholar
  33. 33.
    Cabana MD, Davis MM. Improving physician adherence to cholesterol management guidelines. Manag Care. 2002;11:18–22.Google Scholar
  34. 34.
    Pallazola V, Hla D, Arvanitis M, et al. Major dyslipidemia guidelines and their discrepancies: a need for consensus. 2008., Accessed June 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Hospital Universitario Gregorio MarañónMadridSpain
  2. 2.Medical Affairs at MylanMadridSpain
  3. 3.Outcomes’10CastellónSpain

Personalised recommendations